The albumin is what NIH had contamination problems with a while back. Usage of this product in the manufacture of DCs may have led to the opportunity for a more closed system process in an expedited manner as the planned Phase 2 combo trial in rGBM had an NIH process patent attached which I believe they might have received after the contamination incident. As a side note, the interest taken by Toucan in Inmune might be the placeholder Linda wanted in case the checkpoint combo patent fell through. Unbeknownst to many Linda is making some really good moves to maintain her leverage with NWBO. Best wishes.
News 
Market Data 
Discover 
